Dr. Rajiv Modi, Chairman and Managing Director, Cadila Pharmaceuticals Ltd. addressing IAMICON 2014 (Indravadan Ambalal Modi Innovation Conclave) in Ludhiana.
Ludhiana, November 15, 2014: Cadila Pharmaceuticals Limited – one of India’s largest privately-held pharmaceuticals companies – organised the country’s biggest-ever scientific conclave– IAMICON 2014 (Indravadan Ambalal Modi Innovation Conclave)in Ludhiana to celebrate Innovation and Excellence in the Pharmaceuticals and Life Sciences sector. Covering 50 cities across India, IAMICON 2014 will focus on advances in the treatment of Tuberculosis and Cardiovascular diseases.
Dr Rashmi Kerr (DM, Medicine), Gold Medalist from CMC this year, was conferred the ‘Indravadan Ambalal Modi Academic Excellence Award’, which was presented by Chief Guest Dr. S S Gill. Dr K L Dhar was Chairperson for the sessions on ‘Cardiovascular Risk Management’ and ‘Recent Advancements in Tuberculosis’. Conceived to celebrate Innovation and Excellence in the Pharmaceuticals and Life Sciences sector, IAMICON will bring together the world’s brightest minds in Medical Science to discuss and disseminate the latest updates in Science and Medicine.
Dr. Rajiv Modi, Chairman and Managing Director, Cadila Pharmaceuticals Ltd. said, “India’s pharmaceuticals sector has creditable contribution in providing affordable medicines to patients in India and across the globe. There have been bright sparks of innovation in our country, which have not received due attention. By showcasing such efforts every year and promoting the spirit of Indian innovation, IAMICON seeks to pay eternal tribute to our Founder-Chairman Indravadan Ambalal Modi, the legendary Medicine Man of India. In his perennial quest for making medicines affordable to the last man in the society, he accorded high estimportance to research and innovation. He put in path-breaking efforts to have process patents recognized and his initiatives culminated in the amended Indian Patents Act, 1970, which recognized process patents and helped pioneer India’s generics industry.”
IAMICON 2014 is being held on 14-15-16 and 21-22-23November in 50 cities across India. More than 300 national and international speakers and 20,000-plus doctors will participate in India’s biggest medical knowledge conclave.
Amongst the leading R&D companies in India, Cadila Pharmaceuticals has focused on providing innovative solutions for human healthcare. The Company has a noteworthy track record of launching many first-in-the-world innovative products such as Polycap(5-in-1 polypill for prevention and treatment of Cardiovascular Diseases) and Risorine (innovative solution to treat Tuberculosis). In 2013, the Company introduced Mycidac-C – the world’s first active immunotherapy for lung cancer at almost one-tenth the cost of those made by multinational companies.
“Besides the latest updates in medical science, IAMICON 2014 will simultaneously spotlight the work of some eminent practitioners who will focus on advancements in treating TB and Cardiovascular Diseases. Through the ‘Indravadan Ambalal Modi Academic Excellence Awards’, IAMICON will also felicitate and encourage bright doctors with excellent academic performance intheir post-graduate medical studies,” revealed Dr. Modi.
The IAMICON platform will also be used to spread the message of eradicating Tuberculosis from India and is committed to support Government of India’s ‘TB-Mission 2020’. Cadila Pharmaceuticals Ltd is among the few companies worldwide that have continued to invest in R&D to eliminate this deadly disease. According to the World Health Organization, an estimated480,000 people developed Multi-Drug Resistant TB and an estimated 210,000 died from it in 2013. TB is considered one of the largest global killers, with India reporting 230 cases per 100,000 people.
-----------------------------
Readers may send their news/views/feedback to us:
Date:
Saturday, November 15, 2014